[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572904":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group",null,"Patients with metabolic dysfunction-associated fatty liver disease (MAFLD)",[13],"Device: Fibroscan",{"label":15,"type":10,"description":16,"interventionNames":17},"Control group","Healthy control patients",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DEVICE","Fibroscan","Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.",[15,9],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Shimaa A Meshaal, MD","CONTACT","00966559806580","shaimaa.meshaal2013@med.tanta.edu.eg",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Tanta","El-Gharbia","31527","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],31.00192,30.78847,{"lat":42,"lon":41},[45],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Shimaa Abdelmounem Meshaal","Lecturer of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.","100572904","thyroid-dysfunction-and-its-association-with-metabolic-dysfunction-associated-fatty-liver-disease-100572904",false,"NCT06739330","Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Both sexes.\n* Patients with metabolic dysfunction-associated fatty liver disease (MAFLD).\n\nExclusion Criteria:\n\n* History of thyroid disease or treatment (e.g., thyroid nodules, thyroid cancer, hypothyroidism, and hyperthyroidism).\n* Patients with alcoholic liver disease take more than 40g of alcohol (or four units) per day.\n* Viral hepatitis.\n* Pregnant women.",true,"ALL","18 Years",{"count":60,"type":61},150,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.",[65,66],"Thyroid Dysfunction","Metabolic Dysfunction-Associated Fatty Liver Disease","2024-12-19",{"date":69,"type":70},"2024-12-20","ACTUAL",{"date":67,"type":70},{"date":73,"type":61},"2025-05-01",{"name":5,"class":6},1]